Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia

Keyphrases

• Patients with Schizophrenia 100%
• Prefrontal Cortex 100%
• DARPP-32 100%
• Schizophrenic Patients 83%
• Prefrontal Dysfunction 50%
• Control Subjects 33%
• Alzheimer's Disease 33%
• CaMKII 33%
• Glutamate 33%
• Synapsin 33%
• Schizophrenia 16%
• Potent Inhibitor 16%
• Dorsolateral Prefrontal Cortex (DLPFC) 16%
• Dopamine 16%
• Protein Phosphatase 16%
• Phosphoprotein 16%
• Synaptic 16%
• Illness 16%
• 2 Receptor 16%
• Dopamine Receptor 16%
• Immunoblotting 16%
• N-methyl-D-aspartate 16%
• Postmortem Samples 16%
• Glutamate Receptors 16%
• Selective Reduction 16%
• Ion Channels 16%
• Between-subject 16%
• Autolysis 16%
• Confounding Influences 16%
• Neurotransmitter Dopamine 16%
• Pathophysiological Changes 16%

Neuroscience

• Prefrontal Cortex 100%
• Phosphoprotein DARPP 32 100%
• Typical Antipsychotic 50%
• Alzheimer's Disease 33%
• Synapsin I 33%
• Glutamic Acid 33%
• Calcium Calmodulin Dependent Protein Kinase II 33%
• Receptor 33%
• Aspartic Acid 16%
• Neurotransmitter 16%
• Dorsolateral Prefrontal Cortex 16%
• Phosphoprotein 16%
• Dopamine Receptor 16%
• Phosphoprotein Phosphatase 1 16%
• Glutamate Receptor 16%
• Ion Channel 16%
• Immunoblotting 16%